Ionis Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Ionis Pharmaceuticals, Inc. (IONS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $267.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $267.95M, a 40.73% decline year-over-year.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $246.09M, a 86.98% increase year-over-year.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $203.33M, a 10.26% decline year-over-year.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $156.72M, a 17.12% increase year-over-year.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $943.71M, a 33.83% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $705.14M, a 10.48% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $787.65M, a 34.10% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $587.37M, a 27.53% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $267.95M 10-Q · filed 2026-07-29 | $514.04M 10-Q · filed 2026-07-29 | $717.37M derived: sum of 3 quarters · filed 2026-07-29 | $874.09M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $246.09M 10-Q · filed 2026-04-29 | $449.42M derived: sum of 2 quarters · filed 2026-04-29 | $606.14M derived: sum of 3 quarters · filed 2026-04-29 | $1.06B derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $203.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $360.05M derived: sum of 2 quarters · filed 2026-02-26 | $812.10M derived: sum of 3 quarters · filed 2026-07-29 | $943.71M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $156.72M 10-Q · filed 2025-10-29 | $608.77M derived: sum of 2 quarters · filed 2026-07-29 | $740.38M 10-Q · filed 2025-10-29 | $966.96M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $452.05M 10-Q · filed 2026-07-29 | $583.66M 10-Q · filed 2026-07-29 | $810.24M derived: sum of 3 quarters · filed 2026-07-29 | $944.05M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $131.61M 10-Q · filed 2026-04-29 | $358.19M derived: sum of 2 quarters · filed 2026-04-29 | $492.00M derived: sum of 3 quarters · filed 2026-04-29 | $717.25M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $226.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $360.39M derived: sum of 2 quarters · filed 2026-02-26 | $585.64M derived: sum of 3 quarters · filed 2026-02-26 | $705.14M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $133.81M 10-Q · filed 2025-10-29 | $359.06M derived: sum of 2 quarters · filed 2025-10-29 | $478.56M 10-Q · filed 2025-10-29 | $803.07M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $225.25M 10-Q · filed 2025-07-30 | $344.75M 10-Q · filed 2025-07-30 | $669.25M derived: sum of 3 quarters · filed 2026-02-26 | $813.46M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $119.50M 10-Q · filed 2025-04-30 | $444.00M derived: sum of 2 quarters · filed 2026-02-26 | $588.21M derived: sum of 3 quarters · filed 2026-02-26 | $776.62M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $324.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $468.71M derived: sum of 2 quarters · filed 2026-02-26 | $657.12M derived: sum of 3 quarters · filed 2026-02-26 | $787.65M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $144.21M 10-Q · filed 2024-11-06 | $332.62M derived: sum of 2 quarters · filed 2024-11-06 | $463.14M 10-Q · filed 2024-11-06 | $615.03M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | $188.41M 10-Q · filed 2024-08-01 | $318.94M 10-Q · filed 2024-08-01 | $470.82M derived: sum of 3 quarters · filed 2025-02-19 | $630.59M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | $130.52M 10-Q · filed 2024-05-07 | $282.41M derived: sum of 2 quarters · filed 2025-02-19 | $442.18M derived: sum of 3 quarters · filed 2025-02-19 | $575.97M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | $151.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $311.66M derived: sum of 2 quarters · filed 2025-02-19 | $445.45M derived: sum of 3 quarters · filed 2025-02-19 | $587.37M 10-K · filed 2025-02-19 | |
| 2022-09-30 | $159.77M 10-Q · filed 2023-11-02 | $293.56M derived: sum of 2 quarters · filed 2023-11-02 | $435.48M 10-Q · filed 2023-11-02 | $875.48M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | $133.79M 10-Q · filed 2023-08-09 | $275.71M 10-Q · filed 2023-08-09 | $715.72M derived: sum of 3 quarters · filed 2024-02-21 | $848.81M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | $141.92M 10-Q · filed 2023-05-03 | $581.92M derived: sum of 2 quarters · filed 2024-02-21 | $715.02M derived: sum of 3 quarters · filed 2024-02-21 | $840.77M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $440.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $573.10M derived: sum of 2 quarters · filed 2024-02-21 | $698.85M derived: sum of 3 quarters · filed 2024-02-21 | $810.46M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $133.09M 10-Q · filed 2022-11-09 | $258.84M derived: sum of 2 quarters · filed 2022-11-09 | $370.45M 10-Q · filed 2022-11-09 | $660.73M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | $125.75M 10-Q · filed 2022-08-09 | $237.36M 10-Q · filed 2022-08-09 | $527.64M derived: sum of 3 quarters · filed 2023-02-22 | $687.72M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $111.61M 10-Q · filed 2022-05-04 | $401.89M derived: sum of 2 quarters · filed 2023-02-22 | $561.97M derived: sum of 3 quarters · filed 2023-02-22 | $707.50M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $290.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $450.36M derived: sum of 2 quarters · filed 2023-02-22 | $595.90M derived: sum of 3 quarters · filed 2023-02-22 | $729.26M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $160.08M 10-Q · filed 2021-11-03 | $305.62M derived: sum of 2 quarters · filed 2021-11-03 | $438.98M 10-Q · filed 2021-11-03 | $932.66M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $145.54M 10-Q · filed 2021-08-04 | $278.90M 10-Q · filed 2021-08-04 | $772.59M derived: sum of 3 quarters · filed 2022-02-25 | $940.48M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | $133.37M 10-Q · filed 2021-05-05 | $627.05M derived: sum of 2 quarters · filed 2022-02-25 | $794.94M derived: sum of 3 quarters · filed 2022-02-25 | $958.75M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $493.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $661.57M derived: sum of 2 quarters · filed 2022-02-25 | $825.39M derived: sum of 3 quarters · filed 2022-02-25 | $1.12B 10-K · filed 2022-02-25 | |
| 2019-09-30 | $167.89M 10-Q · filed 2020-11-04 | $331.70M derived: sum of 2 quarters · filed 2020-11-04 | $628.92M 10-Q · filed 2020-11-04 | $821.03M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $163.81M 10-Q · filed 2020-08-05 | $461.03M 10-Q · filed 2020-08-05 | $653.14M derived: sum of 3 quarters · filed 2021-02-24 | $798.54M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $297.21M 10-Q · filed 2020-05-06 | $489.33M derived: sum of 2 quarters · filed 2021-02-24 | $634.72M derived: sum of 3 quarters · filed 2021-02-24 | $752.47M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $192.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $337.51M derived: sum of 2 quarters · filed 2021-02-24 | $455.26M derived: sum of 3 quarters · filed 2021-02-24 | $599.67M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $145.40M 10-Q · filed 2019-11-06 | $263.14M derived: sum of 2 quarters · filed 2019-11-06 | $407.56M 10-Q · filed 2019-11-06 | $575.35M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $117.75M 10-Q · filed 2019-08-08 | $262.17M 10-Q · filed 2019-08-08 | $429.96M derived: sum of 3 quarters · filed 2020-03-02 | $548.27M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $144.42M 10-Q · filed 2019-05-09 | $312.21M derived: sum of 2 quarters · filed 2020-03-02 | $430.52M derived: sum of 3 quarters · filed 2020-03-02 | $542.80M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $167.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $286.11M derived: sum of 2 quarters · filed 2020-03-02 | $398.38M derived: sum of 3 quarters · filed 2020-03-02 | $514.18M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $118.31M 10-Q · filed 2018-11-06 | $230.59M derived: sum of 2 quarters · filed 2018-11-06 | $346.39M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $112.27M 10-Q · filed 2018-08-07 | $228.07M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $115.80M 10-Q · filed 2018-05-07 | ||||
| 2016-12-31 | $372.78M 10-K · filed 2019-03-01 | ||||
| 2015-05-31 | $91.20M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |